PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Acuitas® MDRO Gene Test Approved by NY State Department of Health
GAITHERSBURG, Md. , July 12, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the New York State Department of Health (NYSDOH) has approved the Acuitas® MDRO Gene Test for use by physicians and healthcare providers in the state. The approval of OpGen’s CLIA laboratory to
View HTML
Toggle Summary OpGen Signs Supply Agreement to Use Thermo Fisher Scientific’s Technology to Advance Acuitas® Rapid Test
GAITHERSBURG, Md. , June 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat
View HTML
Toggle Summary OpGen’s Acuitas® Detection Technology Utilized in Publication Revealing Prevalence of CRE in Washington D.C. Healthcare Facilities
Results of over 1,000 patient samples for antibiotic resistant bacteria published today in Infection Control & Hospital Epidemiology GAITHERSBURG, Md. , June 15, 2017 (GLOBE NEWSWIRE) -- OpGen , Inc. (NASDAQ:OPGN) today announced the publication of a citywide evaluation of Washington , D.C.’s
View HTML
Toggle Summary OpGen Data at ASM Microbe 2017 Demonstrates Potential of Acuitas Products for Predicting Antibiotic Susceptibility and Infection Control
GAITHERSBURG, Md. , June 05, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the results from additional studies supporting the capabilities of its Acuitas Rapid Test and Acuitas Whole Genome Sequence Analysis to accurately predict antibiotic resistance and for infection control.
View HTML
Toggle Summary OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
GAITHERSBURG, Md. , May 30, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2 nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of rapid diagnostics to combat multi-drug resistant infections.
View HTML
Toggle Summary OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome Sequencing at ASM Microbe 2017
GAITHERSBURG, Md. , May 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas ® Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA .
View HTML
Toggle Summary OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors
GAITHERSBURG, Md. , April 27, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Tina S. Nova , Ph.D. has been appointed to its Board of Directors.   Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses.
View HTML
Toggle Summary OpGen Announces 2017 First Quarter Financial Results
GAITHERSBURG, Md. , April 26, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the first quarter ended March 31, 2017 and summarized recent business highlights. “In the first quarter, we presented preliminary results supporting the Acuitas®
View HTML
Toggle Summary OpGen Highlights Capabilities of its Acuitas® Technologies to Rapidly Predict Antibiotic Susceptibility Using Drug Resistance Gene Profiles at ECCMID
GAITHERSBURG, Md. , April 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented preliminary results supporting its Acuitas Rapid Test in development to detect antibiotic resistant genes and the use of predictive algorithms from its Acuitas Lighthouse ®
View HTML
Toggle Summary OpGen Announces Date of First Quarter 2017 Financial Results Conference Call
GAITHERSBURG, Md. , April 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its first quarter 2017 financial results after close of market on Wednesday, April 26, 2017 . OpGen’s management team will host a live conference call and webcast at 4:30 p.m.
View HTML